Market Overview

UPDATE: Goldman Sachs Upgrades Quest Diagnostics to Buy on Improved Fundamentals

Related DGX
14 Healthcare Stocks Fundstrat Is Buying
Quest Diagnostics Introduces Dako's PD-L1 Companion Diagnostic for KEYTRUDA®, Merck's Anti-PD-1 Therapy for Metastatic Non-Small Cell Lung Cancer
DaVita (DVA) Introduces Medicare-Specific ACO in Arizona (Zacks)

In a report published Thursday, Goldman Sachs analyst Isaac Ro upgraded the rating on Quest Diagnostics (NYSE: DGX) from Neutral to Buy, and raised the price target from $56.00 to $67.00.

In the report, Ro noted, “We upgrade shares of DGX to Buy from Neutral and raise our 6-month price target to $67 (from $56), which implies 17% upside. After underperforming the S&P, HC peers, and direct comp LH over the past 12 months, we believe DGX is now poised for a turnaround and we see multiple catalysts to drive share outperformance.”

Quest Diagnostics closed on Wednesday at $57.30.

Latest Ratings for DGX

Aug 2015Canaccord GenuityMaintainsBuy
Jun 2015Goldman SachsDowngradesBuyNeutral
Jun 2015KeyBancInitiates Coverage onSector Weight

View More Analyst Ratings for DGX
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Upgrades Analyst Ratings


Related Articles (DGX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters